Shandong Key Laboratory of Biophysics, Institute of Biophysics, Dezhou University, Dezhou 253023, Shandong, China.
Department of Medical Imaging, Dezhou People's Hospital, Dezhou 253023, Shandong, China.
Curr Top Med Chem. 2021;21(18):1692-1709. doi: 10.2174/1568026621666210303145430.
Breast cancer is the most frequent female cancer and one of the leading causes of cancer death in women. There are many chemotherapy agents available for the treatment of breast cancer. Still, the current therapeutic options have not fulfilled the desired outcomes, especially for drug-resistant breast cancer therapy. Thus, there is an urgent need to develop novel anti-breast cancer agents. Coumarin is ubiquitous in natural and synthetic bioactive compounds, and coumarin derivatives readily interact with a variety of enzymes and receptors in breast cancer cells. Moreover, the coumarin-based irosustat as the first-generation steroid sulfatase inhibitor in breast cancer is under clinical evaluation, revealing the potential of coumarin derivatives as novel anti-breast cancer agents. This review aims to describe the recent development of natural and synthetic coumarin derivatives with anti-breast cancer potential, covering the articles published from 2015 to 2020.
乳腺癌是最常见的女性癌症之一，也是女性癌症死亡的主要原因之一。有许多化疗药物可用于治疗乳腺癌。然而，目前的治疗选择并未达到预期的效果，特别是对于耐药性乳腺癌的治疗。因此，迫切需要开发新型的抗乳腺癌药物。香豆素广泛存在于天然和合成的生物活性化合物中，香豆素衍生物容易与乳腺癌细胞中的多种酶和受体相互作用。此外，基于香豆素的伊罗舒他汀作为第一代甾体硫酸酯酶抑制剂正在进行临床评估，这表明香豆素衍生物具有作为新型抗乳腺癌药物的潜力。本综述旨在描述具有抗乳腺癌潜力的天然和合成香豆素衍生物的最新研究进展，涵盖了 2015 年至 2020 年期间发表的文章。
